PULSE recently sat down with Debbie Hart, President and CEO at BioNJ, the life sciences trade association for New Jersey. For more than 30 years, BioNJ has represented over 400 research-based life sciences organizations across the health care ecosystem – from the largest biopharmaceutical companies to early-stage start-ups. Debbie discusses the unique role that life sciences M&A plays in connecting innovation to patients, supporting a diverse ecosystem and strengthening New Jersey’s status as an innovation hub.
Our conversation with Debbie is below:
PULSE: Why does M&A play such a unique and fundamental role in the life sciences industry compared with other sectors?
Debbie: M&A plays a uniquely fundamental role in the life sciences industry because it sits at the intersection of scientific discovery, capital intensity and long development timelines in a way that few other sectors experience. Developing a new therapy is extraordinarily complex, with fewer than 10% of drug candidates that enter clinical trials ultimately receiving regulatory approval. The process can take more than a decade and requires investments exceeding $2-3 billion.
For many emerging biotech companies, advancing a promising discovery beyond early clinical stages is simply not feasible on their own. M&A becomes a critical turning point. It allows larger companies with the capital, technical expertise, regulatory acumen and global infrastructure to bring cutting‑edge innovations to fruition. M&A is essential to sustaining a strong innovation pipeline.
PULSE: How does life sciences M&A support innovation for patients?
Debbie: For patients, M&A in the life sciences sector plays a direct and meaningful role in ensuring that scientific breakthroughs have a path to becoming real-world treatments. By bringing together early-stage innovation with the resources required for large-scale clinical trials, regulatory navigation and global commercialization, M&A helps prevent promising therapies from stalling due to resource constraints. It also enables companies to combine complementary expertise – whether in advanced manufacturing, specialized technologies or disease-area knowledge – accelerating the development of increasingly complex treatments.
PULSE: Many pre-clinical and early-stage programs originate in small companies and start-ups. What challenges do these types of companies face, and how does M&A help these companies advance their innovation?
Debbie: Today, emerging biopharma companies make up roughly 60–70% of the industry’s clinical pipeline, yet many operate with limited capital, small teams and constrained resources. That’s where M&A becomes essential – serving as a bridge that connects cutting‑edge science with the operational strength needed to advance it. By pairing breakthrough innovations with the scale, expertise and infrastructure of larger companies, M&A helps shorten the path to market and ultimately speeds the delivery of life‑changing therapies to patients around the world.
PULSE: How is the role of M&A evolving as treatments become more complex and disease targets more difficult?
Debbie: As treatments become more complex and disease targets more difficult, the role of M&A is evolving from a primarily financial transaction to a strategic enabler of innovation. More and more, companies are diversifying their portfolios through acquisitions and collaborations to tap into the specialized expertise they need to advance next‑generation therapies.
PULSE: Looking ahead, why is predictability in M&A policy and enforcement important for sustaining investment and maintaining U.S. leadership in life sciences innovation?
Debbie: When the rules around M&A feel unclear or unpredictable, deals slow down, money gets more expensive and fewer startups get funded in the first place. This doesn’t just affect individual companies – it affects the country’s competitive edge. The U.S. currently drives about half of all global biopharma R&D spending and remains the top spot for venture‑backed biotech. However, regions in Europe and Asia are actively rolling out policies to attract life sciences investment. If the U.S. becomes a harder or less predictable place for dealmaking, innovation could slow here, while investment and scientific progress migrate elsewhere.